Treatments, drugs, hospitals
GLP-1 users were more than four times as likely to report nail detachment as non-users. The findings, presented at a dermatology congress, have not yet been peer reviewed.
The NEOPRISM-CRC trial gave immunotherapy before surgery instead of the usual post-operative chemotherapy. In 59% of participants, no detectable disease remained after treatment — and none of the 32 had a recurrence at the 33-month mark.
Two research teams have built AI systems that read brain, heart and respiratory activity from one overnight sleep recording. Stanford's model predicted 130 conditions, scoring 0.85 for dementia; a Cleveland Clinic model found the highest-risk patients were more than twice as likely to die as those in the lowest-risk group.
Researchers analysed 300 million laboratory results from over a million women and found 52 of 90 blood markers changed suddenly around the final menstrual period — not gradually, as long assumed. Some specialists have pushed back on the study's "cliff-like" framing, calling it unnecessarily alarming.
A Cambridge and University of East Anglia survey of more than 6,600 people found women were also nearly 50% more likely to receive a psychiatric misdiagnosis. The most common wait for a correct diagnosis was one to two years for women, against up to three months for men.
The 71-year-old announced the news at his Sunday blessing in St. Peter's Square. He is expected to need about a week to recover, and says his planned November visit to South America will still go ahead.
Findings presented in Boston suggest users have biological-age markers younger than comparable untreated people. The signal comes as safety questions grow: lawsuits allege sudden vision loss, and studies have linked the drugs to hair loss and nail disorders.
The treatment uses a single eye injection to make surviving retinal cells respond to amber light, paired with goggles that translate visual scenes into pulses. Six of ten patients hit the threshold for a clinically meaningful improvement.
The study drew on self-reported data from more than 6 million people in 118 countries. The clearest gaps between the sexes were in headache, facial pain and abdominal pain, with researchers pointing to work and care burdens — and social pressure on men not to report pain — as contributing factors.
The Latitude Air Ambulance Gulfstream dropped 13,000 feet in about two minutes before the FAA lost contact. The Coast Guard has since found a debris field off the island.
A shoebox-sized DNA sequencer analyses tumour tissue while surgeons operate, cutting a process that can currently take six to eight weeks. The pilot begins at five specialist centres in England, with no wider rollout date yet confirmed.
More than 57,000 cases have been certified under the federal programme that monitors and treats those exposed to toxic dust at the World Trade Center. About half of all enrolled survivors are now receiving cancer care, up from 35% five years ago.
A new state law opens access to investigational treatments for patients with any condition — the first in the US to let companies bill for experimental care. Protocols need sign-off from a private review board, not the FDA, and only about one in ten drugs that reach this stage are ever fully approved.
NICE rejected the drug on cost grounds in 2024. A higher cost-effectiveness threshold, introduced as part of a deal with the Trump administration in April, and a commercial discount on Enhertu's list price of more than £100,000 a year cleared the way for Thursday's approval.
A global review of 38 studies found that 33 reported significant differences in the treatment men and women received for cardiovascular and kidney conditions. Clinical guidelines almost never recommended different care by sex, leaving the reasons for the gap unexplained.
Preliminary phase 3 results found that none of the children who received a placebo lost enough weight to no longer be classified as obese. The drug is not yet approved for children under 12, and the full data have yet to be peer-reviewed.
The deaths were caused by a dangerous disorder in which the immune system turns against the body's own organs — a known risk of CAR-T therapy. The paused studies had enrolled more than 500 patients across conditions including lupus, multiple sclerosis and rheumatoid arthritis.
Type at least two characters.
